Australia Markets closed

3 ASX cannabis shares to keep your eye on

Lina Lim
Cannabis shares

ASX marijuana shares have come under pressure following general market volatility and capital raisings. While I believe the shares are not in the ‘buy zone’ yet, they are certainly worth keeping an eye out for.

Here are three ASX Marijuana shares to watch:

1. Ecofibre Ltd (ASX: EOF)

Ecofibre listed on the ASX back in March and operates three core business divisions. Ananda Health provides high quality hemp derived nutraceutical products to the United States (US) market. Sales efforts focus on the highly regulated US independent pharmacy market. Ananda Food provides 100% Australian-grown hemp food to the Australian market. And finally, Hemp Black is currently in its pre-commercial phase to provide sustainable hemp-based solutions in the form of high-performance textiles.

I believe Ecofibre shares are not for the faint hearted as it moves in an extremely volatile fashion. However, in the company’s recent full year results posted on 29 July, it cited its first full year of commercialisation with strong capabilities across all business units. The company saw revenues rise 519% from $5.7 million to $35.6 million and net profit after tax (NPAT) up 170% from $8.6 million loss to $6.0 million. Ecofibre shares present high risk/reward, but its business divisions are in their early days and showing promising signs of growth and execution.

2. Althea Group Ltd (ASX: AGH)

Althea has emerged as one of the strongest growing cannabis shares focused on producing, supplying and exporting pharmaceutical grade medicinal cannabis. The company is rapidly growing its patient base, having added 334 patients in the last month, representing the largest number of new patients prescribed Althea products in a single month to date.

Althea had recent raised $30 million at $1.00 per new share for the acquisition of Canadian extraction and contract manufacturing company, Peak Processing Solutions. In my previous article, I stated that capital raisings for growth are typically well received but also require time to stabilise around the raise price. It appears the volatility of the broader market and selling pressure has gotten the better of the Althea share price as it is currently trading for $0.86. I believe investors who want to buy Althea shares should avoid trying to “catch the knife” and wait for the share price to find some consolidation.

3. Elixinol Global Ltd (ASX: EXL)

The Elixinol share price has struggled to gain momentum in the past 3 months despite major highlights including acquiring 25% of US-based Pet Releaf, a leading brand in the high growth cannabidiol (CBD) pet products market, a coveted CBD processor authorisation by the New York State providing the ability to scale future operations, and an operational New Colorado production facility that more than doubles current capacity.

While Elixinol continues to build on its production capabilities, strategic partnerships and distribution agreements, investors should wait for the share price to find some consolidation before considering Elixinol as a growth opportunity. The share price is down an eyewatering 50% since its peak in April and showing no signs of a bottom, yet.

Speaking of marijuana stocks, don't miss the report below.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more

More reading

Motley Fool contributor Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019